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Summary Oestrogen receptors (ER) in breast cancer tumours are highly heterogeneous. In this study, the
variability in the profile of ER isoforms and its relation to progesterone receptor (PgR) levels in breast
tumours has been studied. Using high resolution isoelectric focusing (IEF) 4 ER isoforms can be detected with
pI values of 6.1 (corresponding to the 8S ER), and 6.3, 6.6 and 6.8 (all of which have a sedimentation
coefficient ofapproximately 4S in sucrose density gradients). Data were obtained on the soluble receptors from
supernatants of 66 ER-positive primary breast tumour homogenates using high resolution IEF. In 43 of these
samples PgR levels were also measured. The isoform at pI 6.6 was present in 97.0% of tumours, the isoform at
pl 6.1 in 83.3%, the pl 6.3 isoform 39.4% of tumours and the pl 6.8 isoform in only 33.3% of tumours. Only
12.1% of tumours studied contained the full complement of ER isoforms (pI6.1, 6.3, 6.6 & 6.8). The ER
isoforms at pl 6.1 & 6.8 were only found in PgR-positive (> 10 fmol PgR/mg protein) tumours. Some tumours
contained only a single ER isoform at pI 6.6 or 6.1, but those at pI6.3 and 6.8 were never found singly.
Tumours containing 3 or 4 ER isoforms had significantly higher levels of PgR (>90 fmol/mg protein) than
those with only I or 2 (P<0.001). The presence of ER isoforms at pI6.3 and pI6.8 also significantly
correlated with high levels ofPgR (P<0.001). This variability in the ER isoform profile ofbreast tumours and
their correlation with PgR levels may have a bearing on prognosis and tumour response to endocrine
therapy.
Since the publication of an oestrogen receptor (ER) cDNA
sequence from the breast cancer cell line MCF-7 (Green et
al., 1986) it has been acknowledged that ER is encoded by a
single gene. However, there is evidence that the ER protein
itself is heterogeneous (Jensen et al., 1971; Wittliff et al.,
1972; Puddefoot et al., 1987). Using sucrose density gradient
centrifugation, the ER obtained in the soluble fractions is
recovered either as a large 8S complex or as a smaller 4S
form. Other more sensitive techniques such as isoelectric
focusing (IEF) (Wrange et aL, 1985; Bailleul et al., 1988a,b),
high performance liquid chromatography (HPLC) (Hutchens
et al., 1982; Hutchens et al., 1983; Wielhe et al., 1984) and
DEAE-cellulose chromatography (Wittliff, 1984) have also
shown the ER to be present in various molecular forms.
Previous work from this laboratory using high resolution
isoelectric focusing (IEF) and immunoblotting have shown
that the 4S ER can be resolved into three components with
isoelectric point (pI) values of 6.3, 6.6 and 6.8 while the 8S
ER focuses as a single isoform at pl 6.1 (Marsigliante et al.,
1991a). Furthermore, IEF indicated that all of these isoforms
bind oestradiol, diethylstilboestrol (DES) and tamoxifen
(Marsigliante et al., 199lb).
One important function of the oestrogen receptor is its
involvement in the oestrogenic induction of the progesterone
receptor (PgR) which has been demonstrated at the levels of
protein and mRNA in many tissues (Milgrom et al., 1973;
Vu Hai et al., 1977; Mester & Baulieu, 1977; Horwitz &
McGuire, 1978; Read et al., 1988; Alexander et al., 1989;
Isomaa et al., 1979; May et al., 1989). Furthermore, recent
experiments involving site-directed mutagenesis strongly sug-
gest that oestrogens induce the progesterone receptor gene
through occupied ER binding to an oestrogen responsive
element (ERE) present in the initiation region of the PgR
gene (Savouret et al., 1991).
The relationship between the ER and PgR content of
breast tumours and response to endocrine therapy has been
well documented although approximately 25% of patients
whose tumours contain ER and PgR fail to respond (Wittliff,
1984). It is possible that the heterogeneity of the ER in
tumours from breast cancer patients and in particular the
presence or absence of certain ER isoforms may influence
PgR induction and could therefore be important in prognosis
and response to endocrine therapy.
This report describes studies performed on 66 ER-positive
breast cancer tumours to investigate the heterogeneity in the
distribution of the different ER isoforms present and the
correlation of ER isoform profiles with progesterone receptor
levels.
Materials and methods
Tissue handling
Human breast tumours were obtained at operation from
patients undergoing surgery for primary breast cancer. The
tumours were collected over approximately 12 months, snap
frozen and stored in liquid nitrogen until processed.
All tissue processing was performed at 4°C. The tissue was
homogenised, using a polytron homogeniser, in glycerol
phosphate buffer (10% glycerol, 10mM phosphate, 1.5 mM
EDTA, 5 mM monothioglycerol, pH7.4) 1: 10 w/v (GPB), or
in the same phosphate buffer containing 20 mM Na2MoO4
and 1 ytg ml-' of each of the protease inhibitors aprotinin
and soybean trypsin inhibitor (both from Sigma Chemical
Company Ltd, Poole, Dorset) (GPBI). The homogenates
were centrifuged for 60 min at 100,000 g and the supernatants
were used for receptor analysis.
Dextran coated charcoal (DCC) assay ofER and PgR
ER and PgR were measured by single saturating dose (SSD)
assay which has been shown to correlate very well with
results from Scatchard analysis (McGuire et al., 1977; King
et al., 1979; Puddefoot et al., 1987).
ER were measured by SSD assay using 3[H]-oestradiol
(5 nM final concentration; Amersham International plc,
Amersham, Bucks, UK), in the presence or absence of a
200-fold excess of unlabelled DES (Sigma Chemical Com-
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pany Ltd.). Similarly, PgR were measured using tritiated
progesterone (10 nM final concentration; Amersham Interna-
tional plc), in the presence or absence of a 200-fold excess of
unlabelled norethindrone (Sigma Chemical Company Ltd.).
These incubations were carried out at 4°C for 24 h.
Free hormone was separated from bound by incubation
with DCC (0.5% (w/v) charcoal and 0.05% (w/v) dextran
T70; BDH Chemicals Ltd., Poole, UK) at 4°C followed by
centrifugation at 10,000 g for 5 min. An aliquot of the super-
natant was counted in a liquid scintillation counter. A further
aliquot of these samples was taken for IEF of ER.
Isoelectricfocusing
The IEF gels were cast in slabs of size 125 x 260 mm and
separation was conducted along either the short side (short
run) or the long side (long run) of the gel. Polyacrylamide
gels (2 mm thick), containing 20% (v/v) glycerol and with
high porosity (T = 5%, C = 3%) were used. A pH gradient
was achieved using 1.5% (w/v) LKB ampholine 3.5-10
(LKB, Bromma, Sweden) and 1.0% (w/v) LKB ampholine
5-8. Gels were photopolymerised at room temperature by
means of a TR 26 polymerisation light (Hoefer S.I., San
Francisco, USA), using riboflavin (0.004% v/v) for at least
8 h. IEF was performed in a cold room and the temperature
of the cooling water was kept constant at 4°C using an LKB
Multiphor II system with its chambers filled with 1 M NaOH
to minimise CO2 absorption from the air. Electrode solutions
of 1 M NaOH (cathode) and 1 M H2SO4 (anode) were used.
Gels were pre-focused for 40min at 20 mA/20 W/2000 V
(long run) and for 40 min at 20 mA/20 W/1200 V (short
run).
After DCC extraction, aliquots (270jd) of the radioactive
supernatants (3 mg protein/ml) derived from SSD assay were
loaded near the cathode. The runs were carried out for 4 h
using a 3000xi CC power supply (Bio-Rad, Hemel Hemp-
stead, Herts, UK) at 2500V/20mA/20W, constant power
(long run) and at 1200V/20mA/20 W, constant power, for
1.5 h (short run). A mixture of nine natural proteins (Bio-
Rad) was used for pH calibration. After the run, the gels
were cut into 2.5 mm slices and each slice was incubated with
5 ml scintillation cocktail (Packard Instrument Company Inc,
Illinois, USA) for 24 h at room temperature and radioactivity
assayed.
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Protein determination
Proteins were determined by the method of Lowry, Rose-
brough, Farr & Randall (1951) using BSA as the stan-
dard.
Results
ER isoforms and their distribution in breast cancer tissues
One hundred and five primary breast tumours were analysed
for ER content, using the SSD method, of which 66 (63%)
were ER-positive. These ER-positive tumours (ER concentra-
tions ranging from 11 to 251 fmol/mg protein) were analysed
by short and long run IEF. Short run gels showed only two
radioactive peaks focusing at pI 6.1 and 6.6, which have
previously been shown to represent the 8S and 4S forms of
the ER respectively (Marsigliante et al., 1991b). The higher
resolution oflong run IEF permitted the identification oftwo
additional ER isoforms with pl values of 6.3 and 6.8 (Figure
1). These are also found in rat uterus (data not shown). It
was also possible to detect these 4 ER isoforms in tumours
using immunoblotting of short run IEF separated ER (Mar-
sigliante et al., 1991b). Figure 2 shows four examples of ER
profiles where one or more of the ER isoforms are miss-
ing.
Of the 66 ER-positive specimens examined, 64 (97.0%)
contained the isoform at pI 6.6, 55 (83.3%) contained the
isoform at pI 6.1, 26 (39.4%) contained the isoform at pl 6.3,
and 22 (33.3%) contained the isoform at p16.8.
The ER isoform profiles of the 66 specimens examined by
long run IEF are shown in Table I. Of particular interest is
that only 8 out of the 66 samples (12.1%) contained the full
complement of ER isoforms (pI6.1, 6.3, 6.6 and 6.8) and
only 1 (1.5%) contained the all three 4S isoforms (pI 6.3, 6.6
and 6.8) in the absence of the 8S (pl 6.1) ER. It was also
evident that no tumours contained the isoforms at pl 6.3 or
6.8 as a single isoform.
Correlation between ER isoforms and PgR levels in breast
tumour samples
Analysis of 43 ER-positive breast tumour cytosols was car-
ried out using high resolution IEF and the ER and PgR
I
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Figure 1 Isoelectric focusing analysis (long run) of ER in the 100,000g supernatant from a primary human breast cancer tumour
containing the full complement of ER isoforms (pl 6.1, 6.3, 6.6 and 6.8; 12.1% of tumours showed this profile).ER ISOFORMS AND PgR LEVELS IN BREAST CANCER SAMPLES 1085
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Figure 2 Isoelectric focusing analysis (long run) of ER in the 100,000g supernatant from four different primary breast cancer
tumours where one or more of the ER isoforms is missing. a, Tumour cytosol containing ER isoforms at isoelectric points (pI) 6.6
and 6.1 only (34.8% of tumours showed this profile). b, Tumour cytosol containing ER isoforms at pl 6.1, 6.3 and 6.6 (22.7% of
tumours showed this profile). c, Tumour cytosol containing ER isoform at p1 6.6 only (12.1% of tumours showed this profile). d,
Tumour cytosol containing ER isoforms at pl 6.3, 6.6 and 6.8 (only 1.5% of tumours showed this profile).
Table I ER isoform profiles of 66 human breast cancer tumour
samples using isoelectric focusing (long run)
No. of tumours containing
ER isoforms this ER profile %
6.1 only 2/66 3.0
6.6 only 8/66 12.0
6.1 + 6.6 23/66 34.8
6.3 + 6.6 2/66 3.0
6.1, 6.3 +6.6 15/66 22.7
6.1, 6.6+6.8 7/66 10.6
6.3, 6.6+6.8 1/66 1.5
All 4 8/66 12.1
levels of the samples were measured using the single
saturating dose method. A plot of ER isoform combination
against PgR levels for each tumour is shown in Figure 3.
Statistical analysis on this data using Students' t-tests
showed that tumours containing 3 or 4 ER isoforms
appeared to have levels of PgR greater than 90 fmol/mg
protein while those containing only 1 or 2 ER isoforms had
significantly lower levels of PgR (P<0.001). The presence of
the ER isoforms at pl 6.3 and pl 6.8 also appears to correlate
with the presence of greater than 90 fmol PgR/mg protein
(P<0.00l).
Discussion
Previous work using rat uterus (Jensen et al., 1967) and calf
uterus (Puca et al., 1971; Sica et al., 1976) as sources of
oestrogen receptor (ER) have shown that it exists as two
distinct forms with sedimentation coefficients of 4S and 8S
when studied using sucrose density gradient centrifugation.
Previous work from this laboratory has shown that when
these forms are subjected to IEF, the 8S has a pl value of 6.1
while the 4S is a composite of three separate isoforms with pl
values of 6.3, 6.6 and 6.8 (Marsigliante et al., 1991b).
Oestrogen receptors in human breast cancer samples have
also been shown to express heterogeneity. Using DEAE
chromatography, chromatofocusing, HPLC and IEF (Kute et
al., 1978; Hutchens et al., 1983; Wielhe et al., 1984; Bailleul
et al., 1988a,b) the ER in human breast tumours has also
been shown to exist in several molecular forms. Using similar
approaches to those described in this paper, we have shown
that the ER from some breast tumour samples resolves into
four ER isoforms (Marsigliante et al., 1991b). These binding
components represent subunits and not cleavage products
(mero-receptors) due to proteolytic digestion of the ER
(Jensen et al., 1967; Marsigliante et al., 1991b) and that they
are all capable of binding oestradiol, tamoxifen and diethyl-
stilboestrol (Marsigliante et al., 1991b). The functional
relevance of the three isoforms of the 4S ER still remains
unknown, but their presence in a control (non-pathological)
tissue such as rat uterus cytosol could suggest that they
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Figure 3 Correlation between ER isoform profile and PgR level of 43 human breast cancer tumour cytosols. ER isoforms were
detected by long run IEF and PgR levels were measured by a single saturating dose method.
represent the full complement (together with the 8S form) of
the hormone-reactive ER.
The distribution of the ER isoforms in the 66 ER-positive
breast tumours analysed would suggest that the absence of
the two 4S isoforms at pl 6.3 and 6.8 may be a feature of
cancerous tissue since only 33.3% of tumours contained the
pI 6.8 isoform and 39.4% contained the pI 6.3 isoform. In
contrast 97.0% of tumours contained the 4S isoform at
pI 6.6 and 83.3% contained the 8S (pI 6.1) isoform. Since
our previous studies (Marsigliante et al., 1991b) have shown
that all ER isoforms bind tamoxifen in vitro, the lack of these
4S ER isoforms at pI 6.3 and 6.8, could be important in
response to endocrine treatment.
An important function of the activated ER is its involvement
in the oestrogenic induction of the progesterone receptor and
the presence of PgR has been taken to reflect the activation
of the PgR gene by oestrogen bound to its receptor. ER
activation by oestrogen binding is thought to involve the
formation of the nuclear dimeric form (Muller et al., 1983)
and the ability to do this may require the formation of
oligomeric complexes such as the 8S ER isoform. We have
previously shown that the ability of the 4S ER to form the
8S assembly is an indicator of a fully functional receptor, in
that PgR positivity is associated with the presence of the 8S
oligomer (Marsigliante et al., 1990). Data presented here
shows that tumours containing 3 or 4 ER isoforms appear to
have levels of PgR greater than 90 fmol/mg protein while
those containing only 1 or 2 ER isoforms have significantly
lower levels of PgR. In particular the presence of the ER
isoforms at pI 6.3 and 6.8 correlates significantly with the
presence of high levels of PgR (Figure 3).
These two novel 4S isoforms (pl 6.3 & 6.8) may play an
important role in the oestrogenic induction of the pro-
gesterone receptor gene since their absence is correlated with
a highly significant reduction in expression of the pro-
gesterone receptor. In view of the fact that these novel 4S
isoforms are invariably found in rat uterus, as well as in
some tumours, it is possible that they form an integral part
of the fully functional complement of oestrogen receptors,
and that their absence from many tumours reflects an impair-
ment of receptor function during the progression of malig-
nant disease. In particular, we speculate that the loss of one
or more of these 4S isoforms could therefore compromise the
activity of synthetic ligands (such as tamoxifen) to prevent
activation of transcription functions, resulting in the failure
of endocrine therapy. It is interesting to note that high levels
of the PgR has been shown to be a more important prognos-
tic indicator that ER content (McGuire & Clark, 1985).
Apart from the existence of genetic variants of the ER
gene which exist normally unassociated with tumourigenesis
(Murphy 1990), there is evidence supporting the presence of
variant forms of ER mRNAs in human breast cancers. Gar-
cia et al. (1988, 1989) have identified point mutations in the
A/B domain of the human ER, Fuqua et al. (1991) have
identified ER mRNAs which are deleted in exon 5 or exon 7
and Murphy & Dotzlaw (1989) have identified abnormally
sized ER mRNAs where a substantial portion of the E/F
coding region containing the ligand binding domain of the
normal ER protein is missing. At present, the functional
capabilities of most of the proteins encoded by the mutant
ER mRNAs are unknown but it is possible that the various
ER isoforms seen in this study could be due to the transla-
tion of these variant mRNAs into stable proteins.
Data presented here clearly shows that the ER in human
breast cancer samples is heterogeneous, existing as four
isoforms whose expression varies between tumours. While
their functions remain unknown, it is possible that the two
novel 4S isoforms at pI 6.3 and 6.8 are particularly important
in PgR induction and furthermore, may explain why some
patients with ER-positive tumours respond poorly to endo-
crine treatment.
Clearly further studies would enhance our understanding
of the structure and significance of the 4S ER isoforms and
clarify their importance in the endocrine management of
breast cancer.
We are most grateful to the Breast Cancer Research Trust for
project grant support.
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